BD Receives 510k Clearance For COVID-19, Influenza A/B, RSV Molecular Combination Test
Portfolio Pulse from Benzinga Newsdesk
BD (Becton, Dickinson and Company) has received 510k clearance from the FDA for its COVID-19, Influenza A/B, RSV Molecular Combination Test. The test, which has been available in the US since February through an Emergency Use Authorization, uses a single nasal or nasopharyngeal swab sample to determine if a patient has COVID-19, the flu, or RSV.
August 01, 2023 | 10:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BD's COVID-19, Influenza A/B, RSV Molecular Combination Test has received 510k clearance from the FDA. This could potentially increase the company's market share in the diagnostic testing industry.
The FDA's 510k clearance is a significant regulatory milestone that allows BD to market and sell its COVID-19, Influenza A/B, RSV Molecular Combination Test. This could potentially increase BD's market share in the diagnostic testing industry, leading to increased revenues and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100